Atmiprazole

Active Ingredient

• Atmiprazole 20 contain 20mg Esomeprazole
• Atmiprazole 40 contain 40 mg Esomeprazole

Atmiprazole
contains Esomeprazole as active ingredient which  is a weak base  and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+K+·ATPase - the acid  pump  and  inhibits  both basal  and stimulated  acid  secretion.

Pharmatherabiotic 

Drugs for acid related disorders, proton pump inhibitors.

Market Name

• Atmiprazole 20
• Atmiprazole 40

Dosage Form

• Delayed released capsule

Indication

• Gastro-oesophageal  Reflux Disease  (GORD)         
• • Treatment of erosive reflux oesophagitis
              • Long-term management of patients with healed oesophagitis to prevent relapse
            • Symptomatic treatment of gastro-oesophageal reflux disease (GORD)
  In combination with an appropriate antibacterial therapeutic regimen  for the eradication of Helicobacter pylori
  • Healing of Helicobacter pylori associated duodenal  ulcer
  • Prevention of relapse of peptic ulcers in  patients with  Helicobacter pylori-associated  ulcers.
  Patients requiring continued  NSAID therapy
  • Healing of gastric ulcers associated with  NSAID therapy.
  • Prevention  of gastric and  duodenal ulcers associated with  NSAID therapy,  in patients at risk. Prolonged treatment after I.V.  nduced prevention of rebleeding of peptic ulcers.
  Treatment of Zollinger Ellison Syndrome Adolecents from the age of 12 years Gastro-oesophageal Reflux Disease (GORD),
  • Treatment of erosive  reflux esophagitis
  • Long-term  management of patients with healed esophagitis to prevent relapse
  • Symptomatic treatment of gastro-esophageal reflux disease {GORD)
  In combination with antibiotics in treatment of duodenal ulcer caused  by Helicobacter pylori.

Contraindication

• Hypersensitivity to esomeprazole, substituted benzimidazoles or to any of the excipients
  Esomeprazole should not be used concomitantly with  nelfinavir.

Pregnancy & Lactation

• Pregnancy
  Caution should be exercised when prescribing to pregnant women.
  A moderate amount of data on pregnant women  (between 300-1000 pregnancy outcomes) indicates no ma/formative or foeto/neonatal toxicity of esomeprazole.
• Breast-feeding
  It is  not known  whether esomeprazole is excreted  in  human  breast milk. There  is insufficient information  on the effects of esomeprazole  in  newborns/infants. Therefore Esomeprazole should  not be used during breast-feeding.

Mechanism of Action

• Atmiprazole
  is contains Esomeprazole as active ingredient which  is a weak base  and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+K+·ATPase - the acid  pump  and  inhibits  both basal  and stimulated  acid  secretion.